Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04908280 · ClinicalTrials.gov registry record · Phase 2
Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04908280 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 10 participants.
The verdict
NCT04908280, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the potential efficacy of topical ruxolitinib for the treatment of discoid lupus erythematosus (DLE)
Interventions
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-05-04 |
| Est. Completion | 2024-03-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04908280
The ClinicalTrials.gov registry entry for NCT04908280 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT04908280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04908280 about?
NCT04908280 is a clinical study titled "Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus". The purpose of this study is to assess the potential efficacy of topical ruxolitinib for the treatment of discoid lupus erythematosus (DLE)
What is the current status of trial NCT04908280?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2022-05-04. Estimated completion is 2024-03-04.
What interventions are being tested in trial NCT04908280?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT04908280?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.